This ESMO 2025 poster from CytoDyn presents breakthrough clinical data on leronlimab in metastatic triple-negative breast cancer (mTNBC). Here's what it means, translated into plain language:
???? What They Studied
28 women with stage 4 mTNBC.
These were heavily pre-treated patients (median: 2 prior therapies; some had failed 5).
Leronlimab was given weekly at doses of 350mg, 525mg, or 700mg.
Some also received immune checkpoint inhibitors (ICIs) like atezolizumab, pembrolizumab, or nivolumab.
???? Key Results
Leronlimab was safe and well tolerated
No dose-limiting toxicities, and only minor side effects (grade 1 or 2).
No one dropped out due to the drug.
Survival Outcomes
Median overall survival (mOS): 6.8 months — comparable to leading therapies in this late-line setting.
Long-term survivors:
5 women are still alive after 4+ years.
4 of them are completely cancer-free (NED = No Evidence of Disease).
Mechanism of Action Observed
PD-L1 expression (a key immune marker) increased in 76–88% of patients after leronlimab.
This means leronlimab may be turning “cold tumors” into “hot tumors” — making them responsive to immunotherapy.
Combination with Immunotherapy Was Powerful
All 5 women who showed PD-L1 upregulation and received an ICI (either at the same time or after leronlimab) are still alive at 48 months.
4 of them are NED.
This strongly suggests that leronlimab primes the immune system to make ICIs work better.
???? Supporting Data Highlights
PD-L1 was induced in 88% of patients receiving higher leronlimab doses (525mg+).
Patients whose circulating tumor cells dropped after leronlimab had much better survival (HR=7.11).
Those who also received ICIs had significantly better outcomes (HR=4.14).
???? What This Suggests
Leronlimab may sensitize tumors to immunotherapy by increasing PD-L1 and reducing suppressive immune cells.
The combination of leronlimab + PD-L1 inhibitors could be transformative in mTNBC.
CytoDyn is calling for future prospective studies based on these findings.
???? Why This Matters
Current 3rd+ line treatments in mTNBC are dismal, often with median survival under 7 months.
A drug that is well tolerated, helps the immune system target the cancer, and leaves patients alive and cancer-free after 4 years — even in a small group — is a major signal of potential.
???? What They Studied
28 women with stage 4 mTNBC.
These were heavily pre-treated patients (median: 2 prior therapies; some had failed 5).
Leronlimab was given weekly at doses of 350mg, 525mg, or 700mg.
Some also received immune checkpoint inhibitors (ICIs) like atezolizumab, pembrolizumab, or nivolumab.
???? Key Results
Leronlimab was safe and well tolerated
No dose-limiting toxicities, and only minor side effects (grade 1 or 2).
No one dropped out due to the drug.
Survival Outcomes
Median overall survival (mOS): 6.8 months — comparable to leading therapies in this late-line setting.
Long-term survivors:
5 women are still alive after 4+ years.
4 of them are completely cancer-free (NED = No Evidence of Disease).
Mechanism of Action Observed
PD-L1 expression (a key immune marker) increased in 76–88% of patients after leronlimab.
This means leronlimab may be turning “cold tumors” into “hot tumors” — making them responsive to immunotherapy.
Combination with Immunotherapy Was Powerful
All 5 women who showed PD-L1 upregulation and received an ICI (either at the same time or after leronlimab) are still alive at 48 months.
4 of them are NED.
This strongly suggests that leronlimab primes the immune system to make ICIs work better.
???? Supporting Data Highlights
PD-L1 was induced in 88% of patients receiving higher leronlimab doses (525mg+).
Patients whose circulating tumor cells dropped after leronlimab had much better survival (HR=7.11).
Those who also received ICIs had significantly better outcomes (HR=4.14).
???? What This Suggests
Leronlimab may sensitize tumors to immunotherapy by increasing PD-L1 and reducing suppressive immune cells.
The combination of leronlimab + PD-L1 inhibitors could be transformative in mTNBC.
CytoDyn is calling for future prospective studies based on these findings.
???? Why This Matters
Current 3rd+ line treatments in mTNBC are dismal, often with median survival under 7 months.
A drug that is well tolerated, helps the immune system target the cancer, and leaves patients alive and cancer-free after 4 years — even in a small group — is a major signal of potential.
12
